VC: NovaCardia lands $48M in second round



NovaCardia lands $48M in second round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

NovaCardia
San Diego, CA

$48M
Second

Skyline Ventures and InterWest Partners

NovaCardia which is developing drugs for cardiovascular disease.

Athenagen
South San Francisco, CA

$50M
First

Sanderling Ventures and Clarus Ventures

They will use much of the money to push the development of its candidates for neurovascular diseases.

Amsterdam Molecular Therapeutics
Amsterdam

$27.9M
First

ABN AMRO Capital/Life Sciences, Advent Venture Partners, Gilde Healthcare Partners and Crédit Agricole Private Equity

The money will go to advancing AMT-011--AMT's lead product intended to treat lipoprotein lipase deficiency--from Phase II through to registration.

Gamida Cell
Israel

$16M
Fourth

Israel Healthcare Ventures

The money will be used to expand Gamida Cell's tissue regeneration product pipeline (including a cardiac regeneration product).

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.